The company has made more than 50 deals for its proprietary technology as it looks forward to a potentially “transformative” ...

Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be ...

Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced Dyno-yp2, a novel adeno-associated ...

With up to 2.4 million U.S. cases and over 250 million chronic cases globally, hepatitis B infection persists despite the availability of a vaccine. Vaccines work by immunizing the body against a ...

Assembly and budding of a virus from a membrane microdomain. Viruses have an outer protein shell called a capsid which surrounds the viral nucleic acid. Enveloped viruses, such as HIV, have an ...

Though treatments are available, there is no cure or vaccine from HIV, which impacts about 38 million people worldwide. It's difficult to target the RNA genome of the HIV virus in part because it ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Download Brochure Accurate viral vector characterization in ...

We performed the first ever simulations of simultaneous capsid assembly and encapsulation of a polymer, we characterized the role of the polymer in this cooperative assembly process and obtained ...

Avista Therapeutics, a preclinical gene therapy company built on deep clinical, computational and gene therapy expertise, today announced the significant expansion of its gene therapy platform.